MTNR1B SNP*Food Timing Interaction on Glucose Control (ONTIME-MT)
MTNR1B SNP*Food Timing Interaction on Glucose Control in a Late Eater Mediterranean Population
調査の概要
詳細な説明
Late-night dinner eating is associated with increased risk for type-2-diabetes. The underlying mechanism is unclear. One explanatory hypothesis is that the concurrence of elevated circulating melatonin and high glucose concentrations (characterizing late-eating) leads to impaired glucose-tolerance. However, to date, no study has tested the influence of physiological melatonin concentrations on glucose tolerance. The discovery of melatonin receptor MTNR1B as a diabetes risk gene provides evidence for a role of physiological levels of melatonin in glucose control.
The aim of the current study is to test the hypothesis that the concurrence of meal timing with elevated endogenous melatonin concentrations results in impaired glucose control and that this effect is stronger in homozygous MTNR1B risk carriers than in non-carriers. To do so we will test glucose tolerance using identical mixed meals under two glucose oral tolerance test (OGTT) conditions: a) delayed OGTT or Late Eating (LE): starting1 hour before their usual bed time, b) advanced OGTT or Early Eating (EE): starting 4 hours before habitual bed time, in a randomized, cross-over study design.
These findings could support a clinical application for the screening of this SNP and the possibility of implementing tailored and cost-effective behavioral interventions to prevent type 2 diabetes in vulnerable populations.
These goals will be achieved through a specific approach:
• Interventional (randomized, cross-over controlled trials) (Aim 1): To study the potential interaction between meal timing (dinner) and genetic variants MTNR1B for glucose tolerance in obese women (n=1000).
研究の種類
入学 (予想される)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Marta Garaulet, PHD
- 電話番号:+34 678996368
- メール:garaulet@um.es
研究連絡先のバックアップ
- 名前:Jesus Lopez-Minguez
- 電話番号:+34 660672851
- メール:jesus.lopez5@um.es
研究場所
-
-
-
Murcia、スペイン、30100
- 募集
- University of Murcia
-
コンタクト:
- Marta Garaulet, PHD
- 電話番号:+34 678996368
- メール:garaulet@um.es
-
コンタクト:
- Jesus Lopez-Minguez
- 電話番号:+34 660672851
- メール:jesus.lopez5@um.es
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
IInclusion Criteria:
- Body Mass Index: > 18.5 o < 40 kg/m2
- Age: between 18 and 65 year of age
- Caucasian
- Day workers
Exclusion Criteria:
- Receiving treatment with thermogenic, lipogenic, or drugs
- Diabetes mellitus, chronic renal failure, hepatic diseases, or cancer diagnosis
- Bulimia diagnosis, prone to binge eating
- Undergoing treatment with Type 2 diabetes mellitus (high blood sugar) medications such as Metformin or other non-Metformin oral anti-diabetic drugs such as sulfonylureas, meglitinides, or glitazones
- Undergoing treatment with Corticosteroids/steroids, Growth hormone, Anticoagulant medicines, or blood thinners, Beta blockers for hypertension, Medications for sleep, Fluvoxamine, Opioids or Amphetamines, Tranquilizers, nonsteroidal anti-inflammatory drugs.
- Pregnant
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:MTNR1B CC
Test glucose tolerance in homozygous non-carriers (CC) for MTNR1B rs10830963 in Early OGTT and Late OGTT
|
Test glucose tolerance using identical mixed 75 gr of glucose under early condition (4 hours before habitual bedtime)
Test glucose tolerance using identical mixed 75 gr of glucose under late condition (1 hour before habitual bedtime)
|
実験的:MTNR1B GG
Test glucose tolerance in homozygous (GG) risk allele carriers for MTNR1B rs10830963 in Early OGTT and Late OGTT
|
Test glucose tolerance using identical mixed 75 gr of glucose under early condition (4 hours before habitual bedtime)
Test glucose tolerance using identical mixed 75 gr of glucose under late condition (1 hour before habitual bedtime)
|
実験的:MTNR1B CG
Test glucose tolerance in heterozygous (CG) risk allele carriers for MTNR1B rs10830963 in Early OGTT and Late OGTT
|
Test glucose tolerance using identical mixed 75 gr of glucose under early condition (4 hours before habitual bedtime)
Test glucose tolerance using identical mixed 75 gr of glucose under late condition (1 hour before habitual bedtime)
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Area Under the Curve (AUC) glucose
時間枠:between 0-120 minutes, Visit 2 and 3
|
Investigators will measure insulin and glucose levels for 120 minutes at day time and night time visits, and compare them by genotype at selected loci.
|
between 0-120 minutes, Visit 2 and 3
|
Disposition index
時間枠:between 0-120 minutes, Visit 2 and 3
|
Disposition index will be determined by frequently sampled oral glucose tolerance test
|
between 0-120 minutes, Visit 2 and 3
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Corrected Insulin Response
時間枠:between 0-120 minutes, Visit 2 and 3
|
Corrected Insulin Response
|
between 0-120 minutes, Visit 2 and 3
|
Insulin Sensitivity Index
時間枠:between 0-120 minutes, Visit 2 and 3
|
Insulin Sensitivity Index
|
between 0-120 minutes, Visit 2 and 3
|
Fasting glucose
時間枠:between 0-120 minutes, Visit 2 and 3
|
Fasting glucose
|
between 0-120 minutes, Visit 2 and 3
|
Fasting insulin
時間枠:0-120 minutes, Visit 2 and 3
|
Fasting insulin
|
0-120 minutes, Visit 2 and 3
|
Serum Melatonin
時間枠:at baseline and 120 minutes, Visit 2 and 3
|
Serum Melatonin
|
at baseline and 120 minutes, Visit 2 and 3
|
DLMO
時間枠:between 0-5 hours, Visit 3
|
Dim Light Melatonin Onset
|
between 0-5 hours, Visit 3
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
クロノタイプ
時間枠:ベースラインで
|
朝夕アンケート(MEQ)を使用して評価されます。
|
ベースラインで
|
Temperature record
時間枠:total of 1 week between Visit 1 and 2
|
Measured using temperature sensor
|
total of 1 week between Visit 1 and 2
|
Activity record
時間枠:total of 1 week between Visit 1 and 2
|
Measured using Acceleration Data Logger
|
total of 1 week between Visit 1 and 2
|
Light Exposure
時間枠:total of 1 week between Visit 1 and 2
|
Measured using a light sensor
|
total of 1 week between Visit 1 and 2
|
Sleep Duration
時間枠:total of 1 week between Visit 1 and 2
|
Sleep duration will be computed from self-reported
|
total of 1 week between Visit 1 and 2
|
Total Energy Intake
時間枠:total of 1 week between Visit 1 and 2
|
Total energy intake in kcal/day will be computed from 7-day 24-hr dietary recalls
|
total of 1 week between Visit 1 and 2
|
Dietary Composition
時間枠:total of 1 week between Visit 1 and 2
|
Macronutrient and micronutrient intake will be computed from 7-days of self-reported 24-hr dietary recalls
|
total of 1 week between Visit 1 and 2
|
Dietary Intake Timing
時間枠:total of 1 week between Visit 1 and 2
|
Food timing will be self-reported and averaged across 7-days of 24-hr dietary recalls
|
total of 1 week between Visit 1 and 2
|
Physical activity
時間枠:at baseline
|
Assessed using the International Physical Activity Questionnaire (IPAQ)
|
at baseline
|
Emotional eating
時間枠:at baseline
|
Assessed using the Emotional Eating Questionnaire (EEQ)
|
at baseline
|
Sleep quality
時間枠:at baseline
|
Assessed using the Pittsburgh Sleep Quality Index (PSQI)
|
at baseline
|
Insomnia
時間枠:at baseline
|
Assessed using the Insomnia Severity Index (ISI)
|
at baseline
|
Depression
時間枠:at baseline
|
Assessed using the Patient Health Questionnaire (PHQ-9)
|
at baseline
|
協力者と研究者
スポンサー
捜査官
- スタディチェア:Purificación Gomez Abellan, PHD、Universidad de Murcia
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 2017ES00001
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
Early OGTTの臨床試験
-
University of FloridaPerformance Health引きこもった
-
Institut de Recherches Cliniques de MontrealVertex Pharmaceuticals Incorporated; Université de Montréal完了
-
Saranas, Inc.Cardiovascular Research Foundation, New York; Proxima Clinical Research, Inc.完了
-
Odense University HospitalUniversity of Southern Denmark; Region of Southern Denmark; Municipality of Odense完了
-
Sint Franciscus Gasthuis完了2型糖尿病 | アテローム性動脈硬化症 | 白血球活性化障害 | 家族性複合性高脂血症
-
Brigham and Women's HospitalBiofourmis Inc.積極的、募集していない